Stephanie Tozzo
Chief Tech/Sci/R&D Officer at Avilar Therapeutics, Inc.
Net worth: - $ as of 30/05/2024
Stephanie Tozzo active positions
Companies | Position | Start | End |
---|---|---|---|
Avilar Therapeutics, Inc.
Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Chief Tech/Sci/R&D Officer | 31/10/2021 | - |
Corporate Officer/Principal | 31/10/2021 | - |
Career history of Stephanie Tozzo
Former positions of Stephanie Tozzo
Companies | Position | Start | End |
---|---|---|---|
COHBAR, INC. | Director/Board Member | 10/07/2022 | 09/11/2023 |
Training of Stephanie Tozzo
Université Paris-Saclay | Graduate Degree |
Statistics
International
United States | 3 |
France | 2 |
Operational
Director/Board Member | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Corporate Officer/Principal | 1 |
Sectoral
Health Technology | 2 |
Commercial Services | 2 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
COHBAR, INC. | Health Technology |
Private companies | 1 |
---|---|
Avilar Therapeutics, Inc.
Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Commercial Services |
- Stock Market
- Insiders
- Stephanie Tozzo
- Experience